     |
|||||||||||||||||||
|
|
|||||||||||||||||||
|
|
 2006-08-01 VeraLight Raises usd. 17. 5 Million in Series B Financing to Commercialize Non-Invasive Diabetes Screening Device: Financial News - Yahoo. FinanceResults from a clinical study presented recently at the annual scientific sessions of the American Diabetes Association showed a prototype of the VeraLight Scout was able to identify 20 percent more pre-diabetes and type-2 diabetes patients than the standard fasting glucose test. Scout utilizes proprietary fluorescence spectroscopic technology, does not require patient fasting or a blood draw, and provides results in about 60 seconds. The subject places the palm side of the forearm onto the portable table-top system. Scout shines various wavelengths of light on the skin to stimulate fluorescence that is measured by the machine to provide an indication of diabetes risk based on the presence of biological markers called "advanced glycation endproducts," or AGEs, found in skin. Studies have shown that AGEs correlate well with diabetes biz.yahoo.com VeraLight Raises usd. 17. 5 Million in Series B Financing to Commercialize Non-Invasive Diabetes Screening Device. - ALBUQUERQUE, N. M. , Aug. 1 /PRNewswire/ -- VeraLight, Inc. , a privately held medical device company, today announced the successful completion of a usd. 17. 5 million Series B financing that will be used to complete development, testing, and introduction of the VeraLight Scout diabetes
2006-07-10 Alteon Research Collaborator Receives Funding from Juvenile Diabetes Research Foundation for Diabetic Complications Clinical Study Investigating Alagebrium and Renal Function: Financial News -A Phase 2 protocol for the clinical study has been developed. The randomized, double-blind, placebo-controlled study will test alagebrium in 80 patients with type 1 diabetes between the ages of 18-65 who are in the early stages of kidney disease. There will be an 8-week single-blind, run-in period during which placebo and an ACE inhibitor, standard background therapy for this patient population, will be administered to all patients. This will be followed by 24 weeks of double-blind treatment with either placebo or alagebrium in combination with an ACE inhibitor. Changes in albumin excretion rate will be the primary endpoint of the study. The study, which is expected to be initiated in the fourth quarter of 2006, will be conducted at three sites in Australia and one in Denmark. Notable nephrologist Hans-Henrik Parving, M. D. , biz.yahoo.com Alteon Research Collaborator Receives Funding from Juvenile Diabetes Research Foundation for Diabetic Complications Clinical Study Investigating Alagebrium and Renal Function. - PARSIPPANY, N. J /PRNewswire-FirstCall/ -- Alteon Inc. (Amex: ALT - News) announced today that one of its collaborators, Mark Cooper, M. D. , Ph. D. , Professor, the Baker Heart Research Institute, Melbourne,
2006-07-07 Bayer Acquires Metrika Inc.Bayer HealthCare Diabetes Care is one of the largest self-test diagnostic businesses in the world, supporting customers in 100 countries. Since the introduction of Clinitest(R) reagent tablets in 1941, Bayer has led the way in diabetes care product innovation. The company changed the face of diabetes care in 1969 when it introduced the first portable blood glucose meter and test strips. Bayer HealthCare further innovated diabetes self-management by being the first company to introduce a suite of blood glucose monitors that do not require coding. The BREEZE(R), CONTOUR(R), and DEX(R) 2 blood glucose monitoring systems offer people with diabetes an unparalleled choice in diabetes management systems. Recently, the Canadian and American Arthritis Foundations granted ease-of use designation to the Breeze meter, representing Bayer Diabetes Care, a division of Bayer HealthCare LLC and a member of the Bayer Group (NYSE: BAY), announced today that it has acquired Metrika Inc - Diabetes news medical news health news medical headlines healthcare news health articles medicine articles welfare living
2006-07-12 GlaxoSmithKline :: GlaxoSmithKline Announces FDA Approval and the Launch of Avandamet(R) (Rosiglitazone Maleate and Metformin HCl) as Initial Therapy in the Treatment of Type 2 DiabetesGlaxoSmithKline Announces FDA Approval and the Launch of Avandamet(R) (Rosiglitazone Maleate and Metformin HCl) as Initial Therapy in the Treatment of Type 2 Diabetes Nearly 18 million Americans have type 2 diabetes, the most common form of diabetes. Type 2 diabetes is characterized by high blood sugar levels that occur when the body does not produce enough insulin or does not respond properly to its own natural insulin, a condition called insulin resistance. To manage diabetes, it is important for patients to achieve the blood sugar goal set by their physicians. Blood sugar control is measured by the HbA1C test, or A1C, which reflects a persons average blood sugar levels over the previous two to three months. The American Association of Clinical Endocrinologists recommends an A1C of 6. 5 pct. or lower. The American Diabetes Association recommends an A1C of less than 7 pct. Lowering blood sugar levels can help reduce the risk of diabetes-related complications, such as heart disease, stroke, sev.prnewswire.com GlaxoSmithKline announced today FDA approval of Avandamet(R) (rosiglitazone maleate and metformin HCl) for use as initial treatment of type 2 diabetes as an adjunct to diet and exercise. Avandamet was previously approved as a second-line therapy -- it was indicated for use in patients who were uncontrolled on metformin monotherapy. Now, with this recent approval, physicians can start their type
2006-07-21 Managing Glycemic Response :: Nutraceuticals World - Nutritional and Natural Products Industry Center NewsThe current epidemics of obesity and type II diabetes are manifestations of a metabolic pathway, which has not changed to reflect a modern sedentary lifestyle and consumption of readily available calories derived from easily digested foods. David Jenkins, professor of Nutrition at the University of Toronto who pioneered the concept of GI, says that carbohydrates are digested and absorbed in the first 2 feet of the small intestine rather than in the 22 feet that nature gave us. The advantages of following a low GI diet are reported to be lower risks of developing cardiovascular and type 2 diabetes related complications (Ebbeling et al. , 2005). This sounds promising especially when you consider that about 30 pct. of the U. S. population is obese. www.npicenter.com
2006-07-23 Non-invasive Colorectal Cancer Screening thru Private MD Lab ServicesThe following is a sample of the testing available through Private MD Lab Services: autoimmune diseases, blood and blood diseases, prostate cancer disease, diabetes, female specific tests, gastrointestinal diseases, general wellness tests, heart health and cholesterol, hormones and metabolism, infectious diseases, kidney disease, liver disease, male specific tests, musculoskeletal diseases and sexually transmitted diseases. Locate a lab in your area and purchase the PreGen-Plus test. After processing, an e-mail is sent to you with instructions for stool specimen collection, which is placed directly into a pre-paid and pre-packaged airtight container and sealed immediatelythere is no handling of the sample directly. Most test results are available with two or three weeks after your specimen is mailed or carried to the Patient Service Center. State and federal laws require licensed physicians to analyze the test data and provide the results. A second notification is sent to you, and through a secure link you may download the lab results confidentially. Otis A. Plunk, MD, Private MD founder and medical director, has invested in secure, user-friendly software and offers a network of over 1,000 Patient Service Centers for your testing PR: Private MD Labs is very pleased to be able to offer their patients a new, safe and more convenient method for colorectal cancer screening. PreGen-Plus is a test that analyzes human DNA extracted from the patients stool sample and looks for specific DNA mutations known to be associated
2006-07-21 Operating Profit Falls For Roche Diagnostics - Newsroom - Inside INdiana Business with Gerry DickRoche Molecular Diagnostics posted sales growth of 6 pct. for the period, maintaining a market share of around 40 pct. in an increasingly competitive sector. Sales of virology products continued to grow in line with the market, with blood screening also remaining a major contributor to growth. LightCycler SeptiFast Test, which can rapidly and reliably detect and identify 25 bacterial and fungal pathogens responsible for about 90 pct. of all sepsis (blood poisoning) cases, was launched in Europe. In June Roche began rolling out the new automated cobas s 201 modular blood screening system and comprehensive cobas TaqScreen MPX multiplex test across Europe. cobas TaqScreen MPX Test received CE (Conformit Europenne) certification in . US biologics license applications (BLAs) for this test and for cobas TaqScreen WNV Test, for detection Site for Indianas only statewide business television program containing streaming video segments, real time Indiana business news and links to Indianas latest business content. - Inside indiana business gerry dick inside edge inside edge newsletter the edge indiana stock report mark patton indiana business indiana business news indiana business calendar indiana
2006-07-30 Denver Cherry Hills Village Stories Davis and Connor: A very unique storyDavis and Connor: A very unique story Was diagnosed at age five. David had been wetting the bed frequently, urinating outside whenever possible and craving soda pop. Most of this I attributed to his age until one night when he wet the bed about one hour after I had put him down, then wet my bed about 45 minutes later. I called Childrens Hospital "Ask a Nurse" and they questioned whether I had any history of diabetes in my family (which I hadnt) and told me to take Davis to our pediatrician the next day. After our doctor did a simple urine lab test she told me that Davis had type 1 diabetes and to go immediately to the Barbara Davis Center for two days of intensive training. My husband, denver.yourhub.com Join your local community on and contribute news, photos and events about things in your neighborhood. - Denver news Colorado news Denver events reviews information blogs photos schools neighborhood community
2006-07-29 Denver Evergreen Stories Accepting the Challenge, One day at a time.Accepting the Challenge, One day at a time. My wife Lori whom I wed in Chicago 18 years ago and vacationed in Colorado immediately after Casey was born in July of 1996. After camping at Twin Lakes for a week we fell in love with the area and moved here the following year. When Casey started school in 2001 we began to suspect that something was amiss with her health. We took her to a local physician. After a short consultation and a brief description of her symptoms. a quick blood test was done and she was rushed to Childrens Hospital with a life threatening blood/ sugar count. While at Childrens a representative of The Barbara Davis Juvenile Diabetes Center met us at the hospital and began the process of indoctrinating us as the newest members of the Type 1 Diabetes family. Shots, finger blood draws, carbohydrate counting and many sleepless nights followed. School action denver.yourhub.com Join your local community on and contribute news, photos and events about things in your neighborhood. - Denver news Colorado news Denver events reviews information blogs photos schools neighborhood community
2006-07-21 The Sun News On-line national newsIn this regard, the group provides counseling to people. The counselor explains to Daily Sun: "I want to encourage people to test. A lot of people do not know their HIV status. They are also ignorant of mode of transmission. People should go for test in the hospital. Before the test, they should know the implication, what the test is for. If they are positive, what should they do After the test, they should come back to be counseled. Most things are free; the counseling and the drugs, but the test is not free, because some kits are used. The screening is N700. NATIONAL NEWS INDEX FOR SUN NEWS ONLINE, NIGERIAS LEADING TABLOID DAILY NEWSPAPER. - Sun News Online Nigeria Nigerian News tabloid Africa News Africa
|
|
|||||||||||||||||
|
|||||||||||||||||||
